Principal Investigator at Calico
Adam has studied aspects of the biology of aging throughout his career. His graduate work with Judy Campisi at the University of California at Berkeley and the Buck Institute focused on the regulation of inflammatory networks during cellular senescence. He then did postdoctoral work with Steven Artandi at Stanford University, where he developed high content screening methods to identify regulators of telomerase.
Visit website: https://www.calicolabs.com/people/adam-freund-ph-d
See also: Calico - Combating aging and associated diseases. An Alphabet (Google) subsidiary.
Adam Freund News
Arda Therapeutics, new biotech startup aims to delay or reverse disease progression
Lifespan.io (LEAF) - 28-Jan-2022
Tailoring strategies to eliminate bad cells in age-related diseasesRead more...
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
Longevity.Technology interviews Adam Freund - Calico’s Principal Investigator
Longevity Technology - 02-Sep-2020
Will be presenting a viable therapeutic strategy using IGF signaling at ARDD 2020Read more...